---
title: "YABAO PHARM.CORP terminates the clinical research and development work of SY-009"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/258299451.md"
description: "YABAO PHARM.CORP announced the termination of the clinical research and development work for SY-009. After evaluation, it was decided to reasonably allocate R&D resources and focus on advantageous projects. At the same time, in accordance with accounting standards, the full amount of the R&D capitalization for this project will be fully provided for asset impairment, which is expected to reduce the total profit for the year 2025 by 55.7933 million yuan"
datetime: "2025-09-22T08:10:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/258299451.md)
  - [en](https://longbridge.com/en/news/258299451.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/258299451.md)
---

# YABAO PHARM.CORP terminates the clinical research and development work of SY-009

According to the Zhitong Finance APP, YABAO PHARM.CORP (600351.SH) announced that it has recently conducted a prudent assessment of the SY-009 research and development project (hereinafter referred to as "SY-009"). Considering various factors such as project progress, the investment risks of continued development, and future market value, the company has decided to terminate the clinical research and development work of SY-009 in order to reasonably allocate its R&D resources and focus on advantageous projects in its R&D pipeline. Additionally, in accordance with the "Enterprise Accounting Standards" and other relevant regulations, based on the principle of accounting prudence, the company will fully recognize an asset impairment provision for the capitalized amount of the project's R&D.

This asset impairment provision will reduce the company's total profit for the year 2025 by 55.7933 million yuan. The above data is unaudited, and the final accounting treatment and its impact on the company will be subject to the company's disclosed annual report for 2025

### Related Stocks

- [600351.CN](https://longbridge.com/en/quote/600351.CN.md)

## Related News & Research

- [11:44 ETAurisco Pharmaceutical est le premier fabricant mondial d'oligonucléotides génériques à avoir passé avec succès l'inspection de l'USFDA](https://longbridge.com/en/news/295954532.md)
- [Aurisco Pharmaceutical is the First Generic Oligonucleotide Manufacturer in the World successfully inspected by USFDA](https://longbridge.com/en/news/295699391.md)
- [Antwerp diamond sector rejects link between Trump ring and tariff exemption](https://longbridge.com/en/news/295787581.md)
- [13:50 ETDimora Medical's Sacrum Silicone Absorbent Soft Dressing Breaks into Amazon Wound Dressings Top 3](https://longbridge.com/en/news/295830834.md)
- [09:04 ETCategory Disruptor Living Proof Debuts Sheer Clean Dry Shampoo Mist, its First Non-Aerosol Dry Shampoo Inspired by Skincare](https://longbridge.com/en/news/295939104.md)